SELLAS Life Sciences Group, Inc.
General ticker "SLS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $130.3M (TTM average)
SELLAS Life Sciences Group, Inc. follows the US Stock Market performance with the rate: 36.4%.
Estimated limits based on current volatility of 2.5%: low 4.86$, high 5.11$
Factors to consider:
- Total employees count: 16 (-5.9%) as of 2023
- Top business risk factors: Liquidity and credit risks, Economic downturns and volatility, Geopolitical risks, Manufacturing risks, Cybersecurity threats
- Current price 20.2% above estimated high
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.63$, 4.34$]
- 2026-12-31 to 2027-12-31 estimated range: [1.36$, 3.70$]
Financial Metrics affecting the SLS estimates:
- Positive: with PPE of -11.3 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -9.18 <= 0.07
- Positive: Investing cash flow per share per price, % of 0 > -0.65
- Negative: Industry earnings per price (median), % of -14.62 <= 0
- Positive: Inventory ratio change, % of 0 <= 0
- Negative: negative Net income
- Positive: Shareholder equity ratio, % of 90.46 > 64.25
Short-term SLS quotes
Long-term SLS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $37.87MM | $31.51MM | $28.27MM |
| Operating Income | $-37.87MM | $-31.51MM | $-28.27MM |
| Non-Operating Income | $0.53MM | $0.63MM | $1.41MM |
| R&D Expense | $24.01MM | $19.10MM | $16.02MM |
| Income(Loss) | $-37.34MM | $-30.88MM | $-26.86MM |
| Profit(Loss)* | $-37.34MM | $-30.88MM | $-26.86MM |
| Stockholders Equity | $-7.98MM | $9.46MM | $70.87MM |
| Assets | $6.22MM | $19.43MM | $78.34MM |
| Operating Cash Flow | $-31.41MM | $-35.40MM | $-28.39MM |
| Capital expenditure | $5.50MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $-5.50MM | $0.00MM | $0.00MM |
| Financing Cash Flow | $22.32MM | $46.76MM | $86.30MM |
| Earnings Per Share** | $-1.34 | $-0.50 | $-0.25 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.